This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Cassava Sciences said it will stop all trials of its Alzheimer’s disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in…
Reuters Health Information